iSpecimen Inc. Receives Nasdaq Delisting Notice Due to Equity Non-Compliance
Woburn, MA – On June 1, 2026, iSpecimen Inc. (NASDAQ: ISPC) announced that it has received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, notifying the company of its non-compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires issuers to maintain a minimum of \$2,500,000 in stockholders’ equity to continue listing on the Nasdaq Capital Market.
Key Points from the Report
- Non-Compliance Notification: On May 29, 2026, iSpecimen was officially informed by Nasdaq that it failed to meet the equity requirement for continued listing.
- Current Equity Position: As disclosed in the company’s most recent quarterly report (Form 10-Q for the period ended March 31, 2026), iSpecimen’s stockholders’ equity stood at \$814,000—well below the \$2.5 million threshold.
- No Alternative Compliance: Nasdaq noted that as of May 29, 2026, the company also failed to meet alternative continued listing standards, including the market value of listed securities standard or the net income standard.
- Immediate Impact: The notice does not immediately affect the listing or trading of iSpecimen’s common stock, which will continue to trade under the symbol “ISPC” on the Nasdaq Capital Market for the time being.
- Remediation Timeline: iSpecimen has 45 calendar days from the date of the notice to submit a plan to regain compliance with Nasdaq’s requirements. If Nasdaq accepts the plan, the company may be granted an extension of up to 180 calendar days from the date of the notice to evidence compliance.
- Company Response: Management has stated its intention to submit a compliance plan within the required 45-day timeframe. However, there is no assurance that Nasdaq will accept the plan or grant an extension.
Important Information for Shareholders
- Potential Delisting Risk: This notice puts iSpecimen at risk of being delisted from the Nasdaq Capital Market if it cannot regain compliance with the minimum equity requirement within the specified deadlines. Delisting could have significant negative impacts on the company’s liquidity, visibility, and access to capital markets.
- Share Price Sensitivity: The receipt of a Nasdaq delisting notice is typically considered a material event that can lead to increased volatility in the company’s share price, as it raises uncertainty about the company’s continued eligibility to trade on a major exchange.
- Ongoing Trading: Until further notice, the company’s shares will remain listed and tradable under the current ticker symbol “ISPC”.
- Emerging Growth Company Status: The company has indicated that it qualifies as an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
What’s Next?
Investors should closely monitor upcoming announcements from iSpecimen regarding its compliance plan and any feedback or decisions from Nasdaq. The company’s ability to regain compliance—either by raising additional capital, improving its financial position, or pursuing other strategic actions—will be critical in determining whether it can remain listed on the Nasdaq Capital Market.
Summary Table
| Requirement | Nasdaq Standard | iSpecimen Status (as of Mar 31, 2026) |
|---|---|---|
| Stockholders’ Equity | \$2,500,000 minimum | \$814,000 |
| Alternative Standards | Market Value or Net Income | Not Met |
| Remediation Period | 45 days to submit plan, up to 180 days to comply (if plan accepted) | Plan to be submitted |
| Current Trading Symbol | ISPC | ISPC |
| Exchange | Nasdaq Capital Market | Nasdaq Capital Market |
Investor Takeaway
The notice from Nasdaq is a potentially price-sensitive event that introduces significant uncertainty regarding iSpecimen’s future as a publicly traded company on a major exchange. Shareholders and prospective investors should be aware of the heightened risks, increased volatility, and potential for delisting unless the company can successfully implement a plan to regain compliance within the allowed timeframes.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions. The information contained herein is based on public filings and may be subject to change or updates. Neither the author nor this publication takes responsibility for any investment actions taken based on this article.
